2021 World Conference on Lung Cancer (Posters)-FP05. A Biomarker-Directed, Multi-Center Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Lung Cancer

FP05. A Biomarker-Directed, Multi-Center Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Lung Cancer

Back to course

Video Transcription

Video Summary

In this video, Elsan Agnostou from Johns Hopkins discusses a trial in progress focusing on biomarker-directed immunochemotherapy in lung cancer. The study utilizes liquid biopsy approaches to analyze ctDNA levels in lung cancer patients undergoing immune checkpoint blockade treatment. The analysis has revealed distinct patterns of ctDNA-based molecular response that align with patients' clinical outcomes. The trial is conducted in two stages, with the first stage enrolling 50 metastatic NMC patients to determine the optimal time point for molecular response. The second stage involves treatment-naive NMC patients receiving Pembrolizumab alone or in combination with chemotherapy based on ctDNA molecular response. The primary endpoints of the trial include determining optimal time points for ctDNA molecular response and validating the concordance of ctDNA response with radiologic response. Secondary and tertiary endpoints include investigating the association of ctDNA response with survival and performing nuanced analysis of ctDNA features. The trial is currently ongoing with 34 out of 50 planned patients enrolled. The ultimate goal is to incorporate liquid biopsies into clinical cancer care and tailor therapies for immunotherapy patients more effectively. The trial is sponsored by the Cancer Research Institute, the Mark Foundation, and Personal Genome Diagnostics.

Asset Subtitle

Valsamo Anagnostou

Meta Tag

Speaker Valsamo Anagnostou

Topic Liquid Biopsy and Other Non-invasive Diagnostic Modalities

Keywords

biomarker-directed immunochemotherapy

liquid biopsy

ctDNA levels

immune checkpoint blockade treatment

molecular response